Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)

NCT06512337 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06512337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06512337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study to Evaluate the Effectiveness of Deucravacitinib in Patients With Moderate Plaque Psoriasis in Real-World Settings in China (ADMIRE)
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Active, not recruiting
Start date
January 20, 2025
Completion date
March 11, 2027
Enrollment
153 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis